Since PD-L1 expression has been detected in tumor cells of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and pD-1 levels are elevated in tumor-infiltrating T cells, pD-1 blockade therapy in CAR-T cell therapy may improve the efficacy (49). This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.